Cover Image
市場調查報告書

院內感染治療藥市場(藥物:抗菌劑、抗病毒藥物、抗真菌劑;各感染類型:院內感染肺炎、尿道感染、腸胃疾病、血流感染、手術部位感染、其他):全球產業分析、開發平台分析、規模、佔有率、成長、趨勢及預測

Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

出版商 Transparency Market Research 商品編碼 314944
出版日期 內容資訊 英文 121 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
院內感染治療藥市場(藥物:抗菌劑、抗病毒藥物、抗真菌劑;各感染類型:院內感染肺炎、尿道感染、腸胃疾病、血流感染、手術部位感染、其他):全球產業分析、開發平台分析、規模、佔有率、成長、趨勢及預測 Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
出版日期: 2014年09月01日 內容資訊: 英文 121 Pages
簡介

院內感染是醫療相關感染,在醫院和醫療機關住院中的患者發病的感染疾病。複數的抗菌劑對廣泛的院內感染治療效果受到證明。

本報告提供院內感染治療藥市場相關資料、藥物、各感染類型,及各地區分析、市場現狀與市場機會,及參與企業簡介等彙整資料。

第1章 簡介

第2章 摘要整理

第3章 院內感染治療藥市場概要

  • 概要
  • 活動影響分析
  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會
  • 價值鏈分析
  • 波特五力分析
  • 主要企業的市場佔有率
  • 市場魅力分析
  • 競爭環境

第4章 各藥物的院內感染治療藥市場

  • 概要
  • 抗菌劑
  • 抗病毒藥物
  • 抗真菌劑
  • 開發平台分析:市場預測

第5章 院內感染治療藥市場:各主要感染

  • 概要
  • 院內感染肺炎
  • 手術部位感染
  • 尿道感染
  • 腸胃疾病
  • 血流感染
  • 其他

第6章 各地區院內感染治療藥市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第7章 建議

第8章 企業簡介

圖表

目錄

Title: Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections and Other Hospital Infections) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.

This report on hospital infection therapeutics, studies the current as well as future prospects of the market globally. Hospital infections are also referred to as healthcare-associated infections (HCAIs), or nosocomial infections or hospital-acquired infection (HAIs). HAIs can be defined as those infections that occur in patients when they are admitted to a hospital or any other health-care facility with which they were not suffering from at the time of their admission. A Hospital infection also includes those infections that are acquired in the hospital but appear after the discharge of the patient, as well as the occupational infections among hospital staff. Several antimicrobial drugs have proven their effectiveness in treating a range of hospital infections that are globally prevalent at present. This report comprises of an elaborate executive summary, which includes a market snapshot that provides overall information of various segments and sub-segments that are contained in the report. It also provides an overall information and data analysis of the global hospital infection therapeutics market with respect to market segments based on type of drugs used, major hospital infections and geographic regions.

The market for hospital infection therapeutics is segmented into three major therapeutic drug types, namely, antibacterial, antiviral and antifungal drugs. The hospital infection therapeutics market is also segmented on the basis of major hospital infection types, into six major categories, namely, hospital acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections and other hospital infections. The market has been extensively analyzed on the basis of the usefulness, effectiveness and sales revenue of major drug types as well as geographic prevalence of major types of hospital infections. The market size and forecast in terms of USD million for each drug as well as major infection types has been provided for the period 2012 to 2020, considering 2013 as the base year. The report also provides the compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020.

Geographically, the hospital infection therapeutics market has been categorized into four regions namely, North America, Europe, Asia Pacific, and Rest of the World (ROW). The market size and forecast for each of these regions has been provided for the period 2012 to 2020 along with the CAGR for the forecast period 2014 to 2020. The report also comprises a section on pipeline analysis for this market that includes sales forecast for various drugs currently under phase III clinical trials and expected to be launched during the forecast period. Major pipeline drugs that have been included in the report are Amikacin Inhale, CAZ AVI, Ceftolozane/Tazobactam, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin and Tedizolid. The research study also incorporates the competitive scenario in these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of this market and future opportunities has been provided in the market overview section. This section of the report also deals with market attractiveness analysis, Porter's five forces analysis and competitive analysis of the key players in 2013 in the global hospital infection therapeutics market.

A list of recommendations has been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their share. The report also profiles major players of the hospital infection therapeutics market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi.

The global hospital infection therapeutics market is segmented as follows:

Hospital Infection Therapeutics Market, by Drug Type

  • Antibacterial Drugs
  • Antiviral Drugs
  • Antifungal Drugs

Hospital Infection Therapeutics Market, by Major Infections

  • Hospital-Acquired Pneumonia
  • Surgical Site Infections
  • Urinary Tract Infections
  • Gastrointestinal Disorders
  • Bloodstream Infections
  • Other Hospital Infections

Hospital Infection Therapeutics Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

Table of Contents

Chapter 1 - Introduction

  • 1.1. Report Description
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Assumptions

Chapter 2 - Executive Summary

  • 2.1. Market Snapshot: Global Hospital Infection Therapeutics Market
  • 2.2. Comparative Analysis: Global Hospital Infection Therapeutics Market, by Geography, 2013 & 2020 (Value %)

Chapter 3 - Hospital Infection Therapeutics Market Overview

  • 3.1. Introduction
  • 3.2. Event Impact Analysis
  • 3.3. Market Drivers
    • 3.3.1. High Prevalence of Various Hospital Infections Driving the Demand for Anti-infective Drugs
    • 3.3.2. High Susceptibility of Neonatal Population in a Healthcare Setting Giving Rise to Different Hospital Infections
    • 3.3.3. Lack of Skilled Nursing Staff in Developing and Underdeveloped Economies is Increasing the Prevalence of HAIs
  • 3.4. Market Restraints
    • 3.4.1. Increasing Hospital Surveillance and Infection Control Programs in Developed Countries Leading to a Decline in Number of Hospital Infections
    • 3.4.2. Increasing Number of Multi-drug resistant Bacterial Strains making Presently Available Antibacterial Drugs Obsolete
  • 3.5. Market Opportunities
    • 3.5.1. High Number of Pipeline Drug Molecules for Specific Treatment of HAIs
    • 3.5.2. Increasing Incidences of Hospital Infections and High Unmet Needs in Low to Medium Income Countries of the World
  • 3.6. Value Chain Analysis
  • 3.7. Porter's Five Forces Analysis: Global Hospital Infection Therapeutics Market
    • 3.7.1. Bargaining Power of Suppliers
    • 3.7.2. Bargaining Power of Buyers
    • 3.7.3. Threat of Substitutes
    • 3.7.4. Threat of New Entrants
    • 3.7.5. Competitive Rivalry
  • 3.8. Market Attractiveness Analysis: Global Hospital Infection Therapeutics Market, by Geography
  • 3.9. Competitive Landscape
    • 3.9.1. Market Share Analysis by Key Players: Hospital Infection Therapeutics Market, 2013 (Value %)

Chapter 4 - Hospital Infection Therapeutics Market, by Drug Type

  • 4.1. Overview
    • 4.1.1. Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2012 - 2020 (USD Million)
    • 4.1.2. Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2013 & 2020 (Value %)
  • 4.2. Antibacterial Drugs
    • 4.2.1. Global Antibacterial Drugs in HIT Market Revenue, 2012 - 2020 (USD Million)
  • 4.3. Antiviral Drugs
    • 4.3.1. Global Antiviral Drugs in HIT Market Revenue, 2012 - 2020 (USD Million)
  • 4.4. Antifungal Drugs
    • 4.4.1. Global Antifungal Drugs in HIT Market Revenue, 2012 - 2020 (USD Million)
  • 4.5. Pipeline Analysis: Market Forecast
    • 4.5.1. Amikacin Inhale
      • 4.5.1.1. Global Amikacin Inhale Market Revenue (Expected), 2016 - 2020 (USD Million)
    • 4.5.2. CAZ AVI (Ceftazidime/avibactum)
      • 4.5.2.1. Global CAZ AVI Market Revenue (Expected), 2015 - 2020 (USD Million)
    • 4.5.3. Ceftolozane/Tazobactam
      • 4.5.3.1. Global Ceftolozane/tazobactam Market Revenue (Expected), 2015 - 2020 (USD Million)
    • 4.5.4. Dalvance (dalbavancin)
      • 4.5.4.1. Global Dalvance (dalbavancin) Market Revenue (Expected), 2016 - 2020 (USD Million)
    • 4.5.5. Delafloxacin (RX-3341)
      • 4.5.5.1. Global Delafloxacin Market Revenue (Expected), 2015 - 2020 (USD Million)
    • 4.5.6. Eravacycline (TP-434)
      • 4.5.6.1. Global Eravacycline Market Revenue (Expected), 2017 - 2020 (USD Million)
    • 4.5.7. MK-3415A
      • 4.5.7.1. Global MK-3415A Market Revenue (Expected), 2016 - 2020 (USD Million)
    • 4.5.8. Oritavancin
      • 4.5.8.1. Global Oritavancin Market Revenue (Expected), 2017 - 2020 (USD Million)
    • 4.5.9. Plazomicin
      • 4.5.9.1. Global Plazomicin Market Revenue (Expected), 2017 - 2020 (USD Million)
    • 4.5.10. Surotomycin (CB-315)
      • 4.5.10.1. Global Surotomycin Market Revenue (Expected), 2017 - 2020 (USD Million)
    • 4.5.11. Tedizolid (TR-701)
      • 4.5.11.1. Global Tedizolid Market Revenue (Expected), 2015 - 2020 (USD Million)

Chapter 5 - Hospital Infection Therapeutics Market, by Major Infections

  • 5.1. Overview
    • 5.1.1. Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2012 - 2020 (USD Million)
    • 5.1.2. Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2013 & 2020 (Value %)
  • 5.2. Hospital-Acquired Pneumonia (HAP)
    • 5.2.1. Global HAP Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 5.3. Surgical Site Infections (SSIs)
    • 5.3.1. Global Surgical Site Infection Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 5.4. Urinary Tract Infections (UTIs)
    • 5.4.1. Global UTI Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 5.5. Gastrointestinal Disorders
    • 5.5.1. Global Gastrointestinal Disorders Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 5.6. Bloodstream Infections
    • 5.6.1. Global Bloodstream Infection Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 5.7. Other Hospital Infections
    • 5.7.1. Global Other Hospital Infection Therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 6 - Hospital infection therapeutics Market, by Geography

  • 6.1. Overview
    • 6.1.1. Global Hospital infection therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.5. Rest of the World (RoW)
    • 6.5.1. RoW Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 7 - Recommendations

Chapter 8. -Company Profiles

  • 8.1. Actavis plc
    • 8.1.1. Company Overview
    • 8.1.2. Financial Overview
    • 8.1.3. Product Portfolio
    • 8.1.4. Business Strategies
    • 8.1.5. Recent Developments
  • 8.2. AstraZeneca plc
    • 8.2.1. Company Overview
    • 8.2.2. Financial Overview
    • 8.2.3. Product Portfolio
    • 8.2.4. Business Strategies
    • 8.2.5. Recent Developments
  • 8.3. Bayer AG
    • 8.3.1. Company Overview
    • 8.3.2. Financial Overview
    • 8.3.3. Product Portfolio
    • 8.3.4. Business Strategies
    • 8.3.5. Recent Developments
  • 8.4. Bristol-Myers Squibb Company
    • 8.4.1. Company Overview
    • 8.4.2. Financial Overview
    • 8.4.3. Product Portfolio
    • 8.4.4. Business Strategies
    • 8.4.5. Recent Developments
  • 8.5. Cubist Pharmaceuticals, Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Financial Overview
    • 8.5.3. Product Portfolio
    • 8.5.4. Business Strategies
    • 8.5.5. Recent Developments
  • 8.6. GlaxoSmithKline plc
    • 8.6.1. Company Overview
    • 8.6.2. Financial Overview
    • 8.6.3. Product Portfolio
    • 8.6.4. Business Strategies
    • 8.6.5. Recent Developments
  • 8.7. Johnson & Johnson Services, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Financial Overview
    • 8.7.3. Product Portfolio
    • 8.7.4. Business Strategies
    • 8.7.5. Recent Developments
  • 8.8. Merck & Co., Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Financial Overview
    • 8.8.3. Product Portfolio
    • 8.8.4. Business Strategies
    • 8.8.5. Recent Developments
  • 8.9. Pfizer, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Financial Overview
    • 8.9.3. Product Portfolio
    • 8.9.4. Business Strategies
    • 8.9.5. Recent Developments
  • 8.10. Sanofi
    • 8.10.1. Company Overview
    • 8.10.2. Financial Overview
    • 8.10.3. Product Portfolio
    • 8.10.4. Business Strategies
    • 8.10.5. Recent Developments

List of Figures

  • FIG. 1: Hospital Infection Therapeutics: Market Segmentation
  • FIG. 2: Global Hospital Infection Therapeutics Market, by Drug Type, 2013 (USD Million)
  • FIG. 3: Global Hospital Infection Therapeutics Market, by Major Infections, 2013 (USD Million)
  • FIG. 4: Comparative Analysis: Global Hospital Infection Therapeutics Market, by Geography, 2013 & 2020 (Value %)
  • FIG. 5: Global Hospital Infection Therapeutics Market: Event Impact Analysis
  • FIG. 6: Global Hospital Infection Therapeutics Market, Value Chain Analysis
  • FIG. 7: Porter's Five Forces Analysis: Global Hospital Infection Therapeutics Market, 2012 - 2020
  • FIG. 8: Market Attractiveness Analysis: Global Hospital Infection Therapeutics Market, by Geography (2013)
  • FIG. 9: Market Share Analysis: Hospital Infection Therapeutics Market, 2013 (Value %)
  • FIG. 10: Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2013 & 2020 (Value %)
  • FIG. 11: Global Antibacterial Drugs in HIT Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 12: Global Antiviral Drugs in HIT Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 13: Global Antifungal Drugs in HIT Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 14: Global Amikacin Inhale Market Revenue (Expected), 2016 - 2020 (USD Million)
  • FIG. 15: Global CAZ AVI Market Revenue (Expected), 2015 - 2020 (USD Million)
  • FIG. 16: Global Ceftolozane/tazobactam Market Revenue (Expected), 2015 - 2020 (USD Million)
  • FIG. 17: Global Dalvance (Dalbavancin) Market Revenue (Expected), 2016 - 2020 (USD Million)
  • FIG. 18: Global Delafloxacin Market Revenue (Expected), 2015 - 2020 (USD Million)
  • FIG. 19: Global Eravacycline Market Revenue (Expected), 2017 - 2020 (USD Million)
  • FIG. 20: Global MK-3415A Market Revenue (Expected), 2016 - 2020 (USD Million)
  • FIG. 21: Global Oritavancin Market Revenue (Expected), 2017 - 2020 (USD Million)
  • FIG. 22: Global Plazomicin Market Revenue (Expected), 2017 - 2020 (USD Million)
  • FIG. 23: Global Surotomycin Market Revenue (Expected), 2017 - 2020 (USD Million)
  • FIG. 24: Global Tedizolid Market Revenue (Expected), 2015 - 2020 (USD Million)
  • FIG. 25: Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2013 & 2020 (Value %)
  • FIG. 26: Global HAP Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 27: Global Surgical Site Infection Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 28: Global UTI Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 29: Global Gastrointestinal Disorders Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 30: Global Bloodstream Infection Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 31: Global Other Hospital Infection Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 32: North America Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 33: Europe Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 34: Asia Pacific Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 35: RoW Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 36: Actavis plc: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 37: AstraZeneca plc: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 38: Bayer AG: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 39: Bristol-Myers Squibb Company: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 40: Cubist Pharmaceuticals, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 41: GlaxoSmithKline plc: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 42: Johnson & Johnson: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 43: Merck & Co., Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 44: Pfizer, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 45: Sanofi: Annual Revenue, 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1: Market Snapshot: Global Hospital Infection Therapeutics Market
  • TABLE 2: Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2012 - 2020 (USD Million)
  • TABLE 3: Comparison of Major Resistant Bacterial Strains Prevalence Against Major Therapeutic Drug Classes, in Respective Years (2008 & 2013)
  • TABLE 4: Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2012 - 2020 (USD Million)
  • TABLE 5: Global Hospital infection therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
Back to Top